HBOX Therapies is a German-based medical device startup that has recently raised $2.3M in seed funding from investors including High-Tech Gründerfonds and TechVision Fonds. The company's groundbreaking technology, HBOX (Hyperbaric Blood Oxygenation), facilitates lung-protective treatment for respiratory patients and has the potential to revolutionize the way oxygen deficiency is treated. The technology works by using pressure to dissolve a large amount of oxygen in the blood, providing a solution for when a patient requires significant amounts of oxygen.

The HBOX technology can also help in the treatment of carbon monoxide poisoning, where it quickly removes the CO from the blood and prevents any secondary damage. The founders and shareholders of HBOX Therapies, Dr. Peter Schlanstein, Dr. Matthias Menne, and Niklas Steuer, bring extensive experience in their respective fields, having worked together at the Institute for Applied Medical Technology (AME) at RWTH Aachen University for many years. With their groundbreaking platform technology, HBOX Therapies is well-positioned to make a significant impact in the medical device industry and improve the lives of patients suffering from respiratory issues.